139 related articles for article (PubMed ID: 31675669)
1. Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
Helmy MM; Mouneir SM
Pharmacol Rep; 2019 Dec; 71(6):1133-1139. PubMed ID: 31675669
[TBL] [Abstract][Full Text] [Related]
2. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
[TBL] [Abstract][Full Text] [Related]
3. Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
Luippold G; Mark M; Klein T; Amann K; Daniel C
Diabetes Res Clin Pract; 2018 Sep; 143():199-203. PubMed ID: 30031047
[TBL] [Abstract][Full Text] [Related]
4. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Reichetzeder C; von Websky K; Tsuprykov O; Mohagheghi Samarin A; Falke LG; Dwi Putra SE; Hasan AA; Antonenko V; Curato C; Rippmann J; Klein T; Hocher B
Br J Pharmacol; 2017 Jul; 174(14):2273-2286. PubMed ID: 28423178
[TBL] [Abstract][Full Text] [Related]
5. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
[TBL] [Abstract][Full Text] [Related]
6. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
Jo CH; Kim S; Park JS; Kim GH
Kidney Blood Press Res; 2018; 43(3):987-999. PubMed ID: 29913457
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Abouelkheir M; El-Metwally TH
Eur J Pharmacol; 2019 Nov; 862():172638. PubMed ID: 31491403
[TBL] [Abstract][Full Text] [Related]
9. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
[TBL] [Abstract][Full Text] [Related]
10. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
[TBL] [Abstract][Full Text] [Related]
11. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Kanasaki K
Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
[TBL] [Abstract][Full Text] [Related]
12. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
13. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Takai S; Sakonjo H; Jin D
J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
[TBL] [Abstract][Full Text] [Related]
14. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Chaykovska L; von Websky K; Rahnenführer J; Alter M; Heiden S; Fuchs H; Runge F; Klein T; Hocher B
PLoS One; 2011; 6(11):e27861. PubMed ID: 22125632
[TBL] [Abstract][Full Text] [Related]
15. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
Kubo A; Hidaka T; Nakayama M; Sasaki Y; Takagi M; Suzuki H; Suzuki Y
BMC Nephrol; 2020 Sep; 21(1):402. PubMed ID: 32948146
[TBL] [Abstract][Full Text] [Related]
19. Nephroprotective effect of saxagliptin against gentamicin-induced nephrotoxicity, emphasis on anti-oxidant, anti-inflammatory and anti-apoptic effects.
Helal MG; Zaki MMAF; Said E
Life Sci; 2018 Sep; 208():64-71. PubMed ID: 30012474
[TBL] [Abstract][Full Text] [Related]
20. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
